Physician profile
Thomas Belknap
NPI 1902023146
$6,141.85
in general payments reported to CMS, 2019-2025
14 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $966 · 2021: $108 · 2022: $17.13 · 2023: $1,754 · 2024: $1,364 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,126 · Food and Beverage: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,126.12 |
| Food and Beverage | $1,140.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spineology INC. | $1,801.20 | 2020-2025 | Optimesh Expandable Interbody Fusion System |
| Arthrex, INC. | $1,300.85 | 2024-2025 | |
| United Orthopedics LLC | $1,075.61 | 2024 | |
| Medtronic USA, INC. | $952.60 | 2020 | |
| Globus Medical, INC. | $732.11 | 2019 | |
| Medtronic, INC. | $77.27 | 2021 | |
| Nevro Corp. | $43.59 | 2024 | Senza |
| Nuvasive, INC. | $29.09 | 2019 | |
| Baxter Healthcare | $27.02 | 2023 | Floseal |
| Depuy Synthes Sales INC. | $23.35 | 2019 | |
| Lemaitre Vascular, INC. | $22.41 | 2023 | Anastoclip Gc 8cm (Medium) |
| Heron Therapeutics, INC. | $20.02 | 2024 | Zynrelef |
| Biotronik Nro, INC. | $19.60 | 2024 | Prospera |
| Bioventus LLC | $17.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Belknap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.